Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor
- 8 March 2001
- journal article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 87 (5), 28-32
- https://doi.org/10.1016/s0002-9149(01)01454-0
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522Atherosclerosis, 2000
- Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the ratAtherosclerosis, 2000
- Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cellsAtherosclerosis, 2000
- Pharmacological properties of ZD4522 — A new HMG-CoA reductase inhibitorAtherosclerosis, 2000
- Drug Treatment of Lipid DisordersNew England Journal of Medicine, 1999
- Lowering LDL CholesterolCirculation, 1999